ANONYMOUS CONTACTABLE MEMBER OF THE PUBLIC v PFIZER

Clinical trial disclosure (Conbriza and Xiapex)

An anonymous, contactable member of the public complained about the information published as ‘Clinical Trial Transparency: an assessment of the disclosure results of company-sponsored trials associated with new medicines approved recently in Europe’. The study was published in Current Medical Research & Opinion (CMRO) on 11 November 2013. The study authors were Dr B Rawal, Research, Medical and Innovation Director at the ABPI and R Deane, a freelance consultant in pharmaceutical marketing and communications. Publication support for the study was funded by the ABPI.

The study surveyed various publicly available information sources for clinical trial registration and disclosure of results searched from 27 December 2012 to 31 January 2013. It covered 53 new medicines (except vaccines and fixed dose combinations) approved for marketing by 34 companies by the European Medicines Agency (EMA) in 2009, 2010 and 2011. It included all completed company-sponsored clinical trials conducted in patients and recorded on a clinical trial registry and/or included in a European Public Assessment Report (EPAR). The CMRO publication did not include the specific data for each product. This was available via a website link and was referred to by the complainant. The study did not aim to assess the content of disclosure against any specific requirements.

The complainant stated that the study detailed a number of companies which had not disclosed their clinical trial results in line with the ABPI for licensed products. The complainant provided a link to relevant information which included the published study plus detailed information for each product that was assessed.

The summary output for each medicine set out the sources for all trials found, irrespective of sponsor and an analysis of publication disclosure in the form of a table which gave details for the studies for Conbriza (bazedoxifene) and Xiapex (collagenase clostridium histolyticum).

The detailed response from Pfizer is given below.

General detailed comments from the Panel are given below.

With regard to Xiapex, the Panel noted the CMRO publication in that two of the eleven evaluable studies had not been disclosed within the timeframe giving a disclosure percentage of 82%. The percentage disclosed at 31 January 2013 of all trials completed before the end of January 2012 was 91% with one evaluable study not disclosed. A footnote stated that the undisclosed trial was sponsored by Auxilium and was in the process of publication.

The Panel noted Pfizer’s submission that on 29 October 2013 it issued the basic results of the Xiapex trial it sponsored which completed in October 2012. The posting was awaited on clinicaltrials.gov. There was no documentation showing that the results had been made publicly available. The Panel further noted that Pfizer had not provided any evidence that clinicaltrials.gov had agreed to a request for delayed disclosure for example due to publication in a peer reviewed journal. Thus the Panel ruled a breach of the 2012 Code. The delay in disclosure meant that high standards had not been maintained and a breach was ruled. These rulings were appealed. The Panel noted the date of completion of this study and that the results had been provided to clinicaltrials.gov and that a manuscript had been accepted by the Journal of Hand Surgery. On balance the Panel decided that the delay to disclose in these circumstances did not warrant a ruling of a breach of Clause 2 and ruled accordingly.

Upon appeal by Pfizer the Appeal Board noted that Pfizer had not made it clear in its submission to the Panel which of the studies referred to in its response were the evaluable studies and which were the non evaluable studies. The Panel had not been provided with documentation to show that the results had been made publicly available. The Appeal Board noted from Pfizer that the study results had now been publicly disclosed.

The Appeal Board noted from the data provided by Pfizer in its appeal, that the Xiapex Point X study was not completed until October 2012 which was after the cut off date of the end of January 2012 for it to be considered an evaluable study within the CMRO publication. The Appeal Board considered that as the study was non evaluable at the end of January 2012, it was out with the scope of the complaint and so it ruled no breach of the 2012 Code. The appeal was successful.

With regard to Conbriza, the Panel noted the CMRO publication in that five of the eleven evaluable studies had not been disclosed within the timeframe giving a disclosure percentage of 55%. The percentage disclosed at 31 January 2013 of all trials completed before the end of January 2012 was 82%; two studies had not been disclosed. A footnote stated that the undisclosed trials were sponsored by Wyeth prior to acquisition by Pfizer and were not subject to FDAAA801 requirement.

The Panel noted Pfizer’s submission regarding a Phase III Conbriza study which completed in July 2004 and the earliest date of posting of summary results was April 2008. As the date of first approval and commercial availability of Conbriza was May 2010, Pfizer needed to disclose the results before May 2011. Pfizer had done this and thus the Panel ruled no breach of the 2008 Code including Clause 2.
An anonymous, contactable member of the public complained about the information published as ‘Clinical Trial Transparency: an assessment of the disclosure results of company-sponsored trials associated with new medicines approved recently in Europe’. The study was published in Current Medical Research & Opinion (CMRO) on 11 November 2013. The study authors were Dr B Rawal, Research, Medical and Innovation Director at the ABPI and B R Deane, a freelance consultant in pharmaceutical marketing and communications. Publication support for the study was funded by the ABPI.

The study surveyed various publicly available information sources for clinical trial registration and disclosure of results searched from 27 December 2012 to 31 January 2013. It covered 53 new medicines (except vaccines and fixed dose combinations) approved for marketing by 34 companies by the European Medicines Agency (EMA) in 2009, 2010 and 2011. It included all completed company-sponsored clinical trials conducted in patients and recorded on a clinical trial registry and/or included in a European Public Assessment Report (EPAR). The CMRO publication did not include the specific data for each product. This was available via a website link and was referred to by the complainant. The study did not aim to assess the content of disclosure against any specific requirements.

COMPLAINT

The complainant stated that the study detailed a number of companies which had not disclosed their clinical trial results in line with the ABPI for licensed products. The complainant provided a link to relevant information which included the published study plus detailed information for each product that was assessed.

The summary output for each medicine set out the sources for all trials found, irrespective of sponsor and an analysis of publication disclosure in the form of a table which gave details for the studies for Conbriza (bazedoxifene) and Xiapex (collagenase clostridium histolyticum) as follows:

### Conbriza

<table>
<thead>
<tr>
<th>Total by phase</th>
<th>Total</th>
<th>Unevaluable</th>
<th>Evaluable</th>
<th>Disclosed in timeframe</th>
<th>Disclosure percentage</th>
<th>Complete before end January 2012</th>
<th>Disclosed at all</th>
<th>Disclosure percentage at 31 January 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I &amp; II</td>
<td>4</td>
<td>0</td>
<td>4</td>
<td>1</td>
<td>25%</td>
<td>4</td>
<td>3</td>
<td>75%</td>
</tr>
<tr>
<td>Phase III</td>
<td>7</td>
<td>0</td>
<td>7</td>
<td>5</td>
<td>71%</td>
<td>7</td>
<td>6</td>
<td>86%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>11</td>
<td>0</td>
<td>11</td>
<td>6</td>
<td>55%</td>
<td>11</td>
<td>9</td>
<td>82%</td>
</tr>
</tbody>
</table>

### Xiapex

<table>
<thead>
<tr>
<th>Total by phase</th>
<th>Total</th>
<th>Unevaluable</th>
<th>Evaluable</th>
<th>Disclosed in timeframe</th>
<th>Disclosure percentage</th>
<th>Complete before end January 2012</th>
<th>Disclosed at all</th>
<th>Disclosure percentage at 31 January 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I &amp; II</td>
<td>4</td>
<td>0</td>
<td>4</td>
<td>3</td>
<td>75%</td>
<td>4</td>
<td>3</td>
<td>75%</td>
</tr>
<tr>
<td>Phase III</td>
<td>12</td>
<td>5</td>
<td>7</td>
<td>6</td>
<td>86%</td>
<td>7</td>
<td>7</td>
<td>100%</td>
</tr>
<tr>
<td>Phase IV</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0%</td>
<td>0</td>
<td>0</td>
<td>0%</td>
</tr>
<tr>
<td>TOTAL</td>
<td>17</td>
<td>6</td>
<td>11</td>
<td>9</td>
<td>82%</td>
<td>11</td>
<td>10</td>
<td>91%</td>
</tr>
</tbody>
</table>
The explanation of terms given in the documentation was as follows:

<table>
<thead>
<tr>
<th>Total</th>
<th>Total number of trials identified which were completed and/or with results disclosed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unevaluable</td>
<td>Trials within the total which could not be evaluated (due to either trial completion date or publication date being missing or unclear) – excluded from the analysis</td>
</tr>
<tr>
<td>Evaluable</td>
<td>Trials with all criteria present including dates, and hence the base which could be evaluated for the assessment</td>
</tr>
<tr>
<td>Results disclosed in timeframe</td>
<td>Evaluable trials which fully complied with publication requirements, i.e summary results disclosed (in registry or journal) within 12 months of either first regulatory approval date or trial completion date, whichever was later</td>
</tr>
<tr>
<td>Disclosure percentage</td>
<td>Proportion of evaluable trials which were fully disclosed</td>
</tr>
<tr>
<td>Completed before end of January 2012</td>
<td>Number of studies completed before end January 2012 (or already disclosed)</td>
</tr>
<tr>
<td>Results disclosed at all</td>
<td>Number of trials with any publication of results at any time</td>
</tr>
<tr>
<td>Disclosure percentage at 31 January 2013</td>
<td>Proportion of trials completed by end January 2012 which were now disclosed</td>
</tr>
</tbody>
</table>

The complainant listed the companies he/she would like to complain about and this included Pfizer.

The complainant alleged that all of the companies listed had breached Clauses 2, 9 and 21 of the Code.

When writing to Pfizer, the Authority drew attention to Clauses 1.8 and 21.3 of the Second 2012 Edition of the Code and noted that previous versions of the Code might also be relevant.

**RESPONSE**

Pfizer submitted that the disclosure of clinical trials information, in accordance with the ABPI Code and other applicable regulatory and self-regulatory guidelines worldwide, was important to public health and the reputation of the pharmaceutical industry. The disclosure of clinical trials information for Xiapex and Conbriza came within the scope of the ABPI Code as described in Clause 21.3. Pfizer submitted that as explained below, it had not breached Clauses 1.8, 2, 9 or 21.

**Xiapex**

Pfizer stated that Auxilium Pharmaceuticals Inc was the originator of Xiapex and sponsored the significant majority of clinical trials. In the EU, pursuant to an agreement with Auxilium, Pfizer was the marketing authorization holder for Xiapex until 9 April 2013, when it was transferred to Auxilium UK Limited. Xiapex had been available to UK patients since its launch in the UK in April 2011.

Pfizer was only the sponsor for Study B1531002 (Point X Study - completed) for which it issued the basic results on 29 October 2013. The posting was awaited on the ClinicalTrials.gov site. The basic results were provided. There were clinical trial sites in the UK, Ireland, Sweden, Germany, France, Italy, Spain, Netherlands, Hungary and Denmark. The primary manuscript for the Point X Study had been accepted for publication in the Journal of Hand Surgery (British).

There was a second study, B1531005, for which Pfizer was the sponsor, and this was an EMA post-approval commitment. This study was ongoing but the sponsorship of it was transferred from Pfizer to Auxilium in June 2013, following the transfer of the marketing authorization. Auxilium would therefore be responsible for the basic results posting. There were clinical trial sites in the UK, Spain, Austria, Norway, Germany, Switzerland, Italy and Belgium. All the other studies conducted with Xiapex were sponsored by Auxilium and therefore Auxilium was responsible for posting/publication of results. This included the study identified as non-disclosed in the CMRO publication.

**Conbriza**

Pfizer stated that Wyeth held the marketing authorization for Conbriza until Pfizer acquired Wyeth, after which the marketing authorization was transferred to Pfizer. Conbriza was centrally approved in the EU in April 2009. A list of countries where the product was authorised was provided. Conbriza had not been launched in all EU markets, and had not been launched in the UK. It had therefore not been available to UK patients outside of clinical trials. A list of launch dates was provided.

Two studies were described as non-disclosed in the publication. However, publications were identified for both studies, but not in time for them to be reflected in the manuscript submitted to CMRO.

The first study was a mammography sub-study from one of the Phase III trials, looking at effects of Conbriza on breast density (Harvey et al 2009). The CT.gov locator was: http://clinicaltrials.gov/ct2/show/NCT00418236?term=NCT00418236&rank=1.

The second study was a Phase II Chinese study that was published in the Chinese Pharmaceutical Journal, evaluating the effects of Conbriza on biochemical markers of bone metabolism in healthy postmenopausal Chinese women (X Ling et al 2007).

Using the raw data spreadsheet compiled for the CMRO publication, Pfizer provided a list of the postings and publications for the Phase II and III Conbriza trials. The publication citations for the above two studies had been added to the spreadsheet.

---

The complaint was upheld in the case of Conbriza. It was not upheld in the case of Xiapex. Both companies were subject to an undertaking to publish the remaining study results in accordance with the Code. A list of launch dates was provided.
Finally, the Phase II and III Conbriza trials and the countries involved in the studies, including whether they included any sites in the UK were listed. Pfizer submitted that this showed that only one Phase III study included a UK site.

A copy of the standard operating procedure (SOP) CT20 POL; Public Disclosure and Authorship was provided.

Pfizer submitted that given that all the trials for which Pfizer had responsibility had been disclosed it denied any breach of Clauses 1.8 or 21 of the Code. High standards had been maintained (no breach of Clause 9) and the company submitted that it had not brought the industry into disrepute (no breach of Clause 2).

**GENERAL COMMENTS FROM THE PANEL**

The Panel noted that the study concluded that the results of over three quarters of all company-sponsored clinical trials were disclosed within a year of completion or regulatory approval and almost 90% were disclosed by 31 January 2013 which suggested transparency was now better than had sometimes been reported previously.

The Panel considered that the first issue to be determined was whether the matter was covered by the ABPI Code. If the research was conducted on behalf of a UK pharmaceutical company (whether directly or via a third party) then it would be covered by the ABPI Code. If a study was run by a non UK company but had UK involvement such as centres, investigators, patients etc it was likely that the Code would apply. The Panel appreciated the global nature of much pharmaceutical company sponsored clinical research and a company located in the UK might not be involved in research that came within the ABPI Code. It was a well established principle that UK pharmaceutical companies were responsible for the activities of overseas affiliates if such activities related to UK health professionals or were carried out in the UK.

Clause 21.3 of the Second 2012 Edition of the Code stated that companies must disclose details of clinical trials in accordance with the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature.

The relevant supplementary information stated that this clause required the provision of details about ongoing clinical trials (which must be registered within 21 days of initiation of patients enrolment) and completed trials for medicines licensed for use in at least one country. Further information was to be found in the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2009 and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature 2010, both at http://clinicaltrials.ifpma.org.

The Panel noted that the first Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases was agreed in 2005 by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Japanese Pharmaceutical Manufacturers Association (JFPMMA) and the Pharmaceutical Research and Manufacturers of America (PhRMA). The announcement was dated 6 January 2005.

The Panel noted that Article 9, Clinical Research and Transparency, of the most recent update of the IFPMA Code of Practice (which came into operation on 1 September 2012) included a statement that companies disclose clinical trial information as set out in the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases (2009) and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature (2010). As companies had, in effect, agreed the joint positions their inclusion in the IFPMA Code should not have made a difference in practice to IFPMA member companies but meant that IFPMA member associations had to amend their codes to reflect Article 9. The Second 2012 Edition of the ABPI Code fully reflected the requirements of the IFPMA Code. The changes introduced in the ABPI Code were to update the date of the Joint Position on the Disclosure of Clinical Trial Information and to include the new requirement to disclose in accordance with the Joint Position on the Publication of Clinical Trial Results. Pharmaceutical companies that were members of national associations but not of IFPMA would have additional disclosure obligations once the national association amended its code to meet IFPMA requirements. The disclosures set out in the joint positions were not required by the EFPIA Codes.

The Panel noted that even if the UK Code did not apply many of the companies listed by the complainant were members of IFPMA and/or EFPIA.

The Panel considered that it was good practice for clinical trial results to be disclosed for medicines which were first approved and commercially available after 6 January 2005 (the date of the first joint position). This was not necessarily a requirement of the ABPI Codes from that date as set out below.

As far as the ABPI Code was concerned, the Panel noted that the first relevant mention of the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2005 was in the supplementary
information to Clause 7.5 of the 2006 Code:

‘Clause 7.5 Data from Clinical Trials

Companies must provide substantiation following a request for it, as set out in Clause 7.5. In addition, when data from clinical trials is used companies must ensure that where necessary that data has been registered in accordance with the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2005.’

Clause 7.5 of the 2006 Code required that substantiation be provided at the request of health professionals or appropriate administrative staff. Substantiation of the validity of indications approved in the marketing authorization was not required. The Panel considered this was not relevant to the complaint being considered which was about disclosure of clinical trial results. The Joint Position 2005 was mentioned in the supplementary information to Clause 21.5 but this did not relate to any Code requirement to disclose clinical trial results.

In the 2008 ABPI Code (which superceded the 2006 Code and came into operation on 1 July 2008 with a transition period until 31 October 2008 for newly introduced requirements), Clause 21 referred to scientific services and Clause 21.3 stated:

‘Companies must disclose details of clinical trials.’

The relevant supplementary information stated:

‘Clause 21.3 Details of Clinical Trials

This clause requires the provision of details about ongoing clinical trials (which must be registered within 21 days of initiation of patients enrolment) and completed trials for medicines licensed for use in at least one country. Further information can be found in the Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 2009 and the Joint Position on the Publication of Clinical Trial Results in the Scientific Literature 2010, both at http://clinicaltrials.ifpma.org.

Details about clinical trials must be limited to factual and non-promotional information. Such information must not constitute promotion to health professionals, appropriate administrative staff or the public.’

The Panel noted that in the 2014 ABPI Code the disclosure requirements which had previously been stated in Clause 21 had been moved to Clause 13. In addition, the supplementary information stated that companies must include on their website information as to where details of the clinical trials could be found. The 2014 Code would come into effect on 1 May 2014 for newly introduced requirements following a transition period from 1 January 2014 until 30 April 2014.

The Panel examined the Joint Position on the Disclosure of Clinical Trial Information which was updated on 10 November 2009 and superseded the Joint Position 2008. With regard to clinical trial registries the document stated that all trials involving human subjects for Phase I and beyond at a minimum should be listed. The details should be posted no later than 21 days after the initiation of enrolment. The details should be posted on a free publicly accessible internet-based registry. Examples were given. Each trial should be given a unique identifier to assist in tracking. The Joint Position 2009 provided a list of information that should be provided and referred to the minimum Trial Registration Data Set published by the World Health Organisation (WHO). The Joint Position 2009 referred to possible competitive sensitivity in relation to certain data elements and that, in exceptional circumstances, this could delay disclosure at the latest until after the medicinal product was first approved in any country for the indication being studied. Examples were given.

The Panel noted that the complaint related to the disclosure of clinical trial results.
With regard to the disclosure of clinical trial results the Joint Position 2009 stated that the results for a medicine that had been approved for marketing and was commercially available in at least one country should be publicly disclosed. The results should be posted no later than one year after the medicine was first approved and commercially available. The results for trials completed after approval should be posted one year after trial completion – an adjustment to this schedule was possible to comply with national laws or regulations or to avoid compromising publication in a peer-reviewed medical journal.

The Joint Position 2009 included a section on implementation dates and the need for companies to establish a verification process.

The Joint Position 2005 stated that the results should be disclosed of all clinical trials other than exploratory trials conducted on a medicine that was approved for marketing and was commercially available in at least one country. The results generally should be posted within one year after the medicine was first approved and commercially available unless such posting would compromise publication in a peer-reviewed medical journal or contravene national laws or regulations. The Joint Position 2008 was dated 18 November 2008 and stated that it superseded the Joint Position 2005 (6 January and 5 September). The Joint Position 2008 stated that results should be posted no later than one year after the product was first approved and commercially available in any country. For trials completed after initial approval these results should be posted no later than one year after trial completion. These schedules would be subject to adjustment to comply with national laws or regulations or to avoid compromising publication in a peer reviewed medical journal.

The Joint Position on the Publication of Clinical Trial Results in the Scientific Literature was announced on 10 June 2010. It stated that all industry sponsored clinical trials should be considered for publication and at a minimum results from all Phase III clinical trials and any clinical trials results of significant medical importance should be submitted for publication. The results of completed trials should be submitted for publication wherever possible within 12 months and no later than 18 months of the completion of clinical trials for already marketed medicines and in the case of investigational medicines the regulatory approval of the new medicine or the decision to discontinue development.

Having examined the various codes and joint positions, the Panel noted that the Joint Position 2005 excluded any clinical trials completed before 6 January 2005. The position changed on 18 November 2008 as the Joint Position 2008 did not have any exclusion relating solely to the date the trial completed. The Joint Position 2009 was similar to the Joint Position 2008 in this regard.

The Panel noted that deciding which Code applied, and thus which joint position, was complicated. It noted that the 2011 Code which, taking account the transition period, came into operation on 1 May 2011 was the first edition of the Code to refer to the Joint Position 2008.

The Panel concluded that from 1 November 2008, (allowing for the transition period) until 30 April 2011 under the 2008 Code companies were required to follow the Joint Position 2005. From 1 May 2011 until 31 October 2012 under the 2012 Code companies were required to follow the Joint Position 2008. Since 1 November 2012 companies were required to follow the Joint Position 2009. The Panel considered that since the 2008 Code companies were, in effect, required to comply with the Joint Position cited in the relevant supplementary information. The relevant supplementary information gave details of what was meant by Clause 21.3 (Clause 13.1 in the 2014 Code). The Panel accepted that the position was clearer in the Second 2012 Edition of the Code. The Panel noted that the 2011 Code should have been updated to refer to the Joint Position 2009.

For medicines first licensed and commercially available in any country from 1 November 2008 until 30 April 2011 the results of clinical trials completed before 6 January 2005 would not have to be posted. From 1 May 2011 there was no exclusion of trials based solely on completion date and so for a product first licensed and commercially available anywhere in the world after 1 May 2011 the applicable joint positions required relevant clinical trial results to be posted within a year of the product being first approved and commercially available or within a year of trial completion for trials completed after the medicine was first available.

Noting that the complaint concerned licensed products the Panel considered that the trigger for disclosure was the date the product was first approved and commercially available anywhere in the world. This would determine which version of the Code (and joint position) applied for trials completed prior to first approval. The next consideration was whether the trial completed before or after this date. For trials completing after the date of first approval, the completion date of the trial would determine which Code applied. The Panel considered that the joint positions encouraged disclosure as soon as possible and by no later than 1 year after first availability or trial completion as explained above. The Panel thus considered that its approach was a fair one. In this regard, it noted that the complaint was about whether or not trial results had been disclosed, all the joint positions referred to disclosure within a one year timeframe and companies needed time to prepare for disclosure of results. The Panel considered that the position concerning unlicensed indications or presentations of otherwise licensed medicines etc would have to be considered on a case by case basis bearing in mind the requirements of the relevant joint position and the legitimate need for companies to protect intellectual property rights. The Panel followed the decision tree set out below which it considered set out all the relevant possibilities.
Is the product licensed and commercially available?

- No requirement to disclose

  UK company involved?
  
  - No
  
  UK involvement centres, investigators, patients?

  - UK Code does not apply. IFPMA Code and/or other national associations codes might apply

  Was product first licensed and available before 1 November 2008 and/or trial completed on or after 1 November 2008?

  - Yes
    
    When did trial complete?

    - Before 5 January 2005
      
      Not covered by the Code and predates any Joint Position

    - 5 January 2005 - 31 October 2008
      
      Not required by the Code

    - 1 November 2008 - 30 April 2011
      
      2008 Code

    - 1 May 2011 - 30 October 2012
      
      2011 Code

    - 1 November 2012 - 30 April 2014
      
      Second 2012 Code

    - 1 May 2014 onwards
      
      2014 Code

  - No
    
    When was product first licensed and available?

    - Before 6 January 2005
      
      No need to disclose

    - After 6 January 2005
      
      Disclose within one year of first licensed and commercially available

Was trial completed before or after first licensed and commercially available?

- Joint Position 2005 refers to all clinical trials other than exploratory trials i.e. hypothesis testing i.e. examine pre-stated question

- Results from exploratory trials should also be disclosed if of significant medical importance and may have an impact on marketed product/labeling

- Joint Position 2008 refers to all confirmatory and exploratory efficacy trials

- Joint Position 2009 refers to all clinical trials in patients from Phase 1 onwards

For trials completed 1 May 2011 - 30 October 2012 see Joint Position 2008 for additional disclosure requirements

For trials completed on or after 1 November 2012 see Joint Position 2009 for additional disclosure requirements

For trials completed before or after first licensed and commercially available?

- 2008 Code

- 2011 Code

- Second 2012 Code

- 2014 Code

- 2014 Code

- 2014 Code

Disclose within one year of first licensed and commercially available

Disclose within one year of completion

Disclose within one year of trial completion

Disclose within one year of first licensed and commercially available

Disclose within one year of completion

Disclose within one year of trial completion

Developed by the Panel when considering the complaint about the disclosure of clinical trial results
During its development of the decision tree, the Panel sought advice from Paul Woods, BPharm MA (Medical Ethics and Law) of Paul Woods Compliance Ltd who provided an opinion. Mr Woods was not provided with details of the complaint or any of the responses. The advice sought was only in relation to the codes and joint positions.

The Panel considered the complaint could be read in two ways: firstly that the companies listed had not disclosed the data referred to in the CMRO publication relating to the products named or secondly, more broadly, that the companies had not disclosed the clinical trial data for the product named i.e there could be studies in addition to those looked at in the CMRO publication. The Panel decided that it would consider these cases in relation to the studies covered by the CMRO publication and not on the broader interpretation. Companies would be well advised to ensure that all the clinical trial results were disclosed as required by the Codes and joint positions. The Panel considered that there was no complaint about whether the results disclosed met the requirements of the joint positions so this was not considered. In the Panel’s view the complaint was only about whether or not study results had been disclosed and the timeframe for such disclosure.

The CMRO publication stated that as far as the IFPMA Joint Position was concerned implementation had been somewhat variable in terms of completeness and timing. The Panel noted that a number of studies were referred to in the CMRO publication as ‘unevaluable’ and these were not specifically mentioned by the complainant. The CMRO publication focussed on the disclosure of evaluable trial results and the Panel only considered those evaluable trials.

The Panel noted that its consideration of these cases relied upon the information provided by the respondent companies. The CMRO publication did not identify the studies evaluated; it only provided quantitative data. The Panel noted that the study ran from 27 December 2012 to 31 January 2013 and was published in November 2013. The Panel considered that companies that might not have been in line with various disclosure requirements had had a significant period of time after the study completed and prior to the current complaint being received to have disclosed any missing information. It appeared that the authors of the CMRO publication had contacted various companies for additional information.

The Panel noted that the case preparation manager raised Clause 1.8 of the Second 2012 Edition with the companies. The supplementary information to Clause 1.8, Applicability of Codes, *inter alia*, referred to the situation when activities involved more than one country or where a pharmaceutical company based in one country was involved in activities in another country. The complainant had not cited Clause 1.8. The Panel noted that any company in breach of any applicable codes, laws or regulations would *de facto* also be in breach of Clause 1.8 of the Code; the converse was true. The Panel thus decided that as far as this complaint was concerned, any consideration of a breach or otherwise of Clause 1.8 was covered by other rulings and it decided, therefore, not to make any ruling regarding this clause (or its equivalent in earlier versions of the Code).

**PANEL RULING IN CASE AUTH/2659/11/13**

**Xiapex**

The Panel noted the CMRO publication in that two of the eleven evaluable studies had not been disclosed within the timeframe giving a disclosure percentage of 82%. The percentage disclosed at 31 January 2013 of all trials completed before the end of January 2012 was 91% with one evaluable study not disclosed. A footnote stated that the undisclosed trial was sponsored by Auxilium and was in the process of publication.

The Panel noted Pfizer’s submission that on 29 October 2013 it issued the basic results of the trial it sponsored which completed in October 2012 and included UK patients. The posting was awaited on clinicaltrials.gov. The Panel examined the material provided by Pfizer. It included a document showing that the results had been provided to clinicaltrials.gov but there was no documentation showing that the results had been made publicly available. The Panel further noted that Pfizer had not provided any evidence that clinicaltrials.gov had agreed to a request for delayed disclosure for example due to publication in a peer reviewed journal. Thus the Panel ruled a breach of Clause 21.3 of the 2012 Code. The delay in disclosure meant that high standards had not been maintained. A breach of Clause 9.1 was ruled. These rulings were appealed. The Panel noted the date of completion of this study and that the results had been provided to clinicaltrials.gov and that a manuscript had been accepted by the Journal of Hand Surgery. On balance the Panel decided that the delay to disclose in these circumstances did not warrant a ruling of a breach of Clause 2. No breach of Clause 2 was ruled.

Pfizer sponsored a second study but this was ongoing and sponsorship had transferred to Auxilium in June 2013. Pfizer submitted that the completed undisclosed trial was an Auxilium trial. The Panel considered that as far as Pfizer was concerned the matter did not come within the scope of the Code and therefore ruled no breach.

**Conbriza**

The Panel noted the CMRO publication in that five of the eleven evaluable studies had not been disclosed within the timeframe giving a disclosure percentage of 55%. The percentage disclosed at 31 January 2013 of all trials completed before the end of January 2012 was 82%; two studies had not been disclosed. A footnote stated that the undisclosed trials were sponsored by Wyeth prior to acquisition by Pfizer and were not subject to FDAAA801 requirement.

The Panel noted the information supplied by Pfizer. This indicated that all the trial results had been disclosed. The Panel noted that Conbriza was approved in April 2009 and first launched in May 2010. This meant that for trials completed before May 2010 the results needed to be disclosed by May 2011. The Panel noted that the results of all eleven evaluable studies had been disclosed by May 2011.
The Panel noted Pfizer’s submission that the two studies referred to in the CMRO publication as not being disclosed by 31 January 2013 had been published (one accepted for publication March 2009 and the other in 2007). The publications had not been identified in time for them to be reflected in the CMRO publication. It appeared to the Panel that neither of these studies involved UK patients.

The Panel considered that Pfizer was responsible under the Code for publication of the Wyeth studies. Conbriza had not been launched in the UK. The Panel was only concerned with studies that were run by the UK company or had UK involvement. The Panel examined the information provided by Pfizer and noted the company’s submission that only one Phase III study involved UK patients. It appeared that this study completed in July 2004 and the earliest date of posting of summary results was April 2008. As the date of first approval and commercial availability of Conbriza was May 2010, Pfizer needed to disclose the results before May 2011. Pfizer had done this and thus met the requirements of the 2008 Code. The Panel ruled no breach of Clause 21.3 and consequently no breach of Clauses 9.1 and 2. The Panel noted that the ten other studies had no UK involvement. The Panel considered that these did not come within the scope of the UK Code and therefore ruled no breach.

APPEAL BY PFIZER

Xiapex
Pfizer understood that the Panel’s ruling with regard to clinical trial disclosure was for evaluable studies only, and one of the criteria for this was that the completion of the study needed to be by the end of January 2012. Pfizer submitted that as the Xiapex Point X study completed in October 2012 (as noted on the raw data spreadsheet for the CMRO publication (copy provided)) it was not an evaluable study, thus it was outwith the scope of the Panel’s decision.

Pfizer appealed the Panel’s rulings of a breach of Clause 9.1 and 21.3.

COMMENTS FROM THE COMPLAINANT
There were no comments from the complainant.

APPEAL BOARD RULING

The Appeal Board noted that Pfizer had not made it clear in its submission to the Panel which of the studies referred to in its response were the evaluable studies and which were the non evaluable studies.

The Appeal Board noted that the Panel had not been provided with documentation to show that the results had been made publicly available. The Appeal Board noted from the Pfizer representatives at the appeal that the study results had now been publicly disclosed.

The Appeal Board noted from the raw data spreadsheet for the CMRO publication, provided by Pfizer in its appeal, that the Xiapex Point X study was not completed until October 2012 which was after the cut off date of the end of January 2012 for it to be considered an evaluable study within the CMRO publication. The Appeal Board considered that as the study at issue was non evaluable at the end of January 2012, it was outwith the scope of the complaint and so it ruled no breach of Clauses 9.1 and 21.3 of the 2012 Code. The appeal was successful.

Complaint received 21 November 2013
Case completed 12 June 2014